Bitard Competitors

bluebird bio has rebranded as Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Follow our new page at the link below!

We have an audacious mission to develop novel therapies for communities with high unmet needs. Where others see challenges, Amylyx sees opportunities that we pursue with urgency, rigorous science, and unwavering commitment. We explore scientific approaches that are tailored to diseases where we can make the greatest difference, agnostic of modality, in order to usher in a new era of advancements. See our community guidelines here: https://www.amylyx.com/social-media-guidelines Please be aware of potential phishing scams imitating Amylyx. All authentic communications from Amylyx will be from the Amylyx.com domain.

At AMAG, aiming higher is in our DNA. We are a company driven to take on tough health challenges and find solutions for patients with complex, underserved conditions. Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicines across a range of therapeutic areas . We also invest in clinical research to expand the body of knowledge in these therapeutic areas. But we don’t stop there. We know that improving health is about more than providing effective therapies. It’s about understanding the lives and needs of the people we serve and working together with doctors, specialists and patient advocates to break down the barriers that stand in the way of better care. Join a team that always remembers why we are here – to find new and better ways to help patients who need our expertise, empathy and understanding. For more information, please visit us at www.amagpharma.com.